DAIT.F Stock Overview

Manufactures and sells pharmaceutical products worldwide. More details

DAIT.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	4/6

Rewards

Trading at 79.3% below our estimate of its fair value

Earnings are forecast to grow 14.82% per year

Risk Analysis

Shares are highly illiquid

Dividend of 3.34% is not well covered by free cash flows

Large one-off items impacting financial results

My Notes

Capture your thoughts, links and company narrative

Daito Pharmaceutical Co.,Ltd. Competitors

Zhengye Biotechnology Holding

NasdaqCM:ZYBT

US$213.7m

Procaps Group

NasdaqGM:PROC

US$171.5m

biote

NasdaqGM:BTMD

US$206.4m

SIGA Technologies

NasdaqGM:SIGA

US$447.0m

Price History & Performance

Summary of share price highs, lows and changes for Daito PharmaceuticalLtd
Historical stock prices
Current Share Price	JP¥13.13
52 Week High	JP¥13.13
52 Week Low	JP¥13.13
Beta	0.28
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	DAIT.F	US Pharmaceuticals	US Market
7D	0%	4.2%	-0.5%
1Y	n/a	5.1%	24.3%

Return vs Industry: Insufficient data to determine how DAIT.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how DAIT.F performed against the US Market.

Price Volatility

Is DAIT.F's price volatile compared to industry and market?
DAIT.F volatility
DAIT.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.6%
Market Average Movement	6.5%
10% most volatile stocks in US Market	18.8%
10% least volatile stocks in US Market	3.3%

Stable Share Price: DAIT.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine DAIT.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1942	1,070	Hiroshi Matsumori	www.daitonet.co.jp

Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. It offers generic drugs, active pharmaceutical ingredients, and over the counter drugs; and contract manufacturing services for formulations products, high-potent drugs, and packaging.

Daito Pharmaceutical Co.,Ltd. Fundamentals Summary

How do Daito PharmaceuticalLtd's earnings and revenue compare to its market cap?
DAIT.F fundamental statistics
Market cap	US$208.00m
Earnings (TTM)	US$17.19m
Revenue (TTM)	US$307.09m

12.1x

P/E Ratio

0.7x

P/S Ratio

Is DAIT.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DAIT.F income statement (TTM)
Revenue	JP¥47.37b
Cost of Revenue	JP¥38.34b
Gross Profit	JP¥9.03b
Other Expenses	JP¥6.38b
Earnings	JP¥2.65b

Last Reported Earnings

Nov 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	173.35
Gross Margin	19.06%
Net Profit Margin	5.60%
Debt/Equity Ratio	21.8%

How did DAIT.F perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

38%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/30 08:56
End of Day Share Price	2025/01/03 00:00
Earnings	2024/11/30
Annual Earnings	2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Daito Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yukichi Okabe	Okasan Securities Co. Ltd.
Takashi Akahane	Tokai Tokyo Intelligence Laboratory Co., Ltd.
Masao Yoshida	Tokai Tokyo Intelligence Laboratory Co., Ltd.

Daito PharmaceuticalLtd OTCPK:DAIT.F Stock Report